Pulmonary patients

Pulmonary Safety in

Pulmonary Safety pr

Not known pulmonary hypertension.

Pulmonary complications

Intestinal obstruction, Pancreatitis

He is obstructing our proceedings.

Epistaxis Pulmonary haemorrhage

Flushing Pulmonary embolism

Pulmonary haemorrhage Uncommon

Pulmonary artery hypertension

Pulmonary eosinophilia

Pulmonary hypertension Pulmonary hypertension is a known complication of Gaucher disease.

Pulmonary hypertension Pulmonary hypertension is a known complication of Gaucher disease.

And that is microvascular obstruction.

hypertension).

5 Pulmonary veno occlusive disease

23 Pulmonary veno occlusive disease

We were hoping to vote on the motion for a resolution without the amendments.

Very rare cough, pulmonary hypertension

Cardiac disorders Common congestive heart failure cardiac dysfunction, pericardial effusion, arrhythmia (including tachycardia), palpitations Uncommon myocardial infarction, pericarditis, ventricular arrhythmia (including ventricular tachycardia), angina pectoris, cardiomegaly Rare cor pulmonale, myocarditis, acute coronary syndrome

Embolism pulmonary, oedema, oedema peripheral

Skin and subcutaneous tissue disorders Very common

Deep venous thrombosis and pulmonary embolism

President. Sir James, your group has already exceeded its speaking time by ten minutes this evening.

Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

History of esophageal or gastrointestinal obstruction or decreased lumen gastrointestinal tract.

Gastro intestinal occlusion, dysphagia, mouth ulcers stomatitis, tongue disorder Uncommon

In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience (see section 4.4).

In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience (see section 4.4).

However, since a significant percentage of these patients were

However, since a significant percentage of these patients were

Interstitial lung disease (including pneumonitis and pulmonary fibrosis)

Acute diffuse infiltrative pulmonary and pericardial disease.

History of esophageal or gastrointestinal obstruction or decreased lumen diameter of the

He must, therefore, intervene where there is any obstruction.

In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience.

Pulmonary events Severe pulmonary events have been reported rarely with the use of Herceptin in the post marketing setting (see 4.8).

Gastrointestinal disorders

Dysphagia, Gastritis, Faecal incontinence, Faecaloma Intestinal obstruction, Pancreatitis, Lip swelling, Cheilitis

We often encounter indifference or have to deal with obstructionism.

Pulmonary changes As with other alpha interferons, pulmonary symptoms, including dyspnoea, pulmonary infiltrates, pneumonia, and pneumonitis have been reported during therapy with Pegasys.

Caution should also be exercised in patients being treated with other sympathomimetics, including decongestants, anorexogenics or amphetamine type psychostimulants, antihypertensive agents, tricyclic antidepressants and other antihistamines.

References External links Emedicine The Merck Manual of Diagnosis and Therapy Cor Pulmonale